^
Association details:
| Biomarker: | TMB-H + EGFR mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug Class: | EGFR inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
High Tumor Mutation Burden Is Associated with Poor Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy
Published date:
08/29/2022
Excerpt:
We retrospectively enrolled patients with locally advanced or metastatic EGFR mutation-positive lung adenocarcinoma who received EGFR-TKIs as the frontline therapy....In multivariate analysis, high TMB was independently associated with a shorter PFS (hazard ratio [HR] = 1.80, p = 0.0427) and shorter OS (HR = 2.05, p = 0.0397) than that of the low TMB group.
DOI:
https://doi.org/10.3390/biomedicines10092109
